Although MDSCs suppress anti-tumor immunity, targeting them therapeutically has proven challenging (64, 65, 66, 67) ILC2s promoted the suppressive capacities of tumor M-MDSCs, and in vitro blockade of ILC2-derived IL-4 and IL-13 reprogrammed M-MDSCs to adopt an immunostimulatory phenotype, promoting IFNγ expression in CD8 T cells. This evidence concerns the gene IL13 and neoplasm.